A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Go Back to All Clinical Trials

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Brief description of study

If you have been diagnosed with colon or rectal cancer, you may qualify to participate in a study evaluating the combination of the drugs eflornithine and sulindac versus these drugs alone to treat your cancer. The main goal of this phase III trial is to compare the effects of eflornithine and sulindac in combination for the treatment of colon and/or rectal cancers. In addition, we would like to study blood samples to understand how much drug is in the blood over time, which is known as pharmacokinetic )PK) testing.

Clinical Study Identifier: s17-00109

ClinicalTrials.gov Identifier: NCT01349881

Perlmutter Cancer Center

Clinical Trials & Research Studies

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Brief description of study

Recruitment Status